睡茄提取物(Withania somnifera Extract) - 药物靶点：SLC8A3_在研适应症：阿尔茨海默症_专利_临床

概要

基本信息

药物类型

中药

别名

Withania somnifera roots extract

靶点

SLC8A3

作用方式

激动剂

作用机制

SLC8A3 agonists(solute carrier family 8 member A3 agonists)

治疗领域

神经系统疾病

在研适应症

阿尔茨海默症

非在研适应症

肌萎缩侧索硬化广泛性焦虑障碍精神分裂症

原研机构-

在研机构

华中科技大学

WellSpring School of Allied Health

非在研机构

University of California, Los Angeles

Sunnybrook Health Sciences Centre

Natreon, Inc.

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

登录后查看时间轴

关联

6

项与睡茄提取物相关的临床试验

CTRI/2024/03/064007

/ Completed临床3期IIT

Effects of Eight weeks Supplementation of Withania Somnifera on Biochemical and Physical Components Among Football Players - Nil

开始日期2024-03-24

申办/合作机构-

NCT05031351

/ Unknown status临床2期IIT

Nuclear Factor Kappa Beta Inhibition in Patients With Amyotrophic Lateral Sclerosis: A Phase II Randomized Placebo Controlled Trial

This is a Phase II, single centre, randomized, parallel, double blind, placebo-controlled clinical trial to determine the safety of Withania somnifera in participants with Amyotrophic Lateral Sclerosis (ALS).

开始日期2021-10-19

申办/合作机构

Sunnybrook Health Sciences Centre

NCT03437668

/ Terminated临床2/3期IIT

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia. A secondary aim is to determine whether WSE reduces measures of positive and negative symptoms (PANSS subscales) and stress scores on the Perceived Stress Scale (PSS).

开始日期2018-12-01

申办/合作机构

University of Maryland

[+1]

100 项与睡茄提取物相关的临床结果

登录后查看更多信息

100 项与睡茄提取物相关的转化医学

登录后查看更多信息

100 项与睡茄提取物相关的专利（医药）

登录后查看更多信息

58

项与睡茄提取物相关的文献（医药）

2024-12-11·Journal of Biomolecular Structure and Dynamics

Withania somnifera extract reduces gastric cancerous properties through inhibition of gankyrin in cellular milieu produced by Helicobacter pylori and Epstein Barr virus

Article

作者: Kumar, Sachin ; Baral, Budhadev ; Jha, Hem Chandra ; Bagde, Pranit Hemant ; Kashyap, Dharmendra ; Roy, Rajarshi ; Kar, Parimal ; Varshney, Nidhi ; Kandpal, Meenakshi

Helicobacter pylori and Epstein Barr virus (EBV) are group1 carcinogens and their role in Gastric cancer (GC) is well established. Previously we have shown that H. pylori and EBV appears to support aggressive gastric oncogenesis through the upregulation of oncoprotein Gankyrin. Natural plant active molecules have the potential to interrupt oncogenesis. Herein, we investigated the potential of Withania somnifera root extract (WSE) as a possible chemotherapeutic agent against host oncoprotein Gankyrin whose expression was altered by H. pylori and EBV-associated modified cellular milieu. The results show that WSE does not have any inhibitory effect on H. pylori and EBV-associated gene transcripts except for the lmps (lmp1, lmp2a, and lmp2B). Moreover, the WSE exert their anticancer activity via host cellular response and decreased the expression of cell-migratory (mmp3 and mmp7); cell-cycle regulator (pcna); antiapoptotic gene (bcl2); increased the expression of the proapoptotic gene (apaf1 and bax); and tumor suppressor (p53, prb, and pten). Knockdown of Gankyrin followed by the treatment of WSE also decreases the expression of TNF-ɑ, Akt, and elevated the expression of NFkB, PARP, Casp3, and Casp9. WSE also reduces cell migration, and genomic instability and forced the cells to commit programmed cell death. Moreover, molecular simulation studies revealed that out of eight active compounds of WSE, only four compounds such as withaferin A (WFA), withanoside IV (WA4), withanolide B (WNB), and withanolide D (WND) showed direct stable interaction with Gankyrin. This article reports for the first time that treatment of WSE decreased the cancerous properties through host cellular response modulation in gastric epithelial cells coinfected with H. pylori and EBV.Communicated by Ramaswamy H. Sarma.

2024-11-01·Human Psychopharmacology: Clinical and Experimental

Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta‐analysis

Review

作者: Raza, Ghana ; Fatima, Kaneez ; Waseem, Areesha ; Muskan, Fariha ; Rashid, Ahmed Mustafa ; Shaikh, Yasmeen ; Khan, Umeed ; Zaheer, Muhammad Kashan ; Shahid, Hiba ; Malik, Javeria ; Jaffery, Syeda Fatima

AbstractObjectiveDespite the historical neurological use of Withania somnifera, limited evidence supports its efficacy for conditions like anxiety and insomnia. Given its known anti‐stress properties, this review evaluated its safety and efficacy for anxiety and insomnia.MethodsWe searched Medline, Cochrane Library, and Google Scholar until August 2023 for randomized controlled trials (RCTs) comparing W. somnifera to placebo in patients with anxiety and/or insomnia. Outcome measures included changes in anxiety levels via the Hamilton Anxiety Scale (HAM‐A), Sleep Onset Latency (SOL), Total Sleep Time (TST), Wake After Sleep Onset (WASO), Total Time in Bed (TIB), Sleep Efficiency (SE), and Pittsburgh Sleep Quality Index (PSQI) score. We utilized a random‐effect model for pooling Mean Differences (MD) with a 95% Confidence Interval (CI). Heterogeneity was assessed through sensitivity and subgroup analysis, and the quality of RCTs was evaluated using the Cochrane revised risk of bias tool.ResultsPooled results from five RCTs (n = 254) demonstrated that W. somnifera significantly reduced HAM‐A scores (MD = −5.96; [95% CI −10.34, −1.59]; P = 0.008; I2 = 98%), as well as sleep parameters such as SOL, TST, PSQI, and SE, but not WASO and TIB.ConclusionWhile W. somnifera extracts yielded promising results, further research with larger sample sizes is needed to confirm its effects on anxiety and insomnia.

2024-07-01·Phytomedicine

Wheat seedlings extract ameliorates sarcopenia in aged mice by regulating protein synthesis and degradation with anti-inflammatory and mitochondrial biogenesis effects

Article

作者: Lee, HanGyeol ; Bae, Heekyong R ; Shin, Su-Kyung ; Kwon, Eun-Young ; Han, Ji-Won ; Seo, Woo Duck ; Moon, So Yeon

BACKGROUNDChronic inflammation, which becomes more prevalent during aging, contributes to sarcopenia by reducing muscle mass and strength.PURPOSEWheat seedlings extract (WSE) is known for its various physiological activities, including anti-inflammation and antioxidant effects. However, its efficacy against sarcopenia is not well documented.STUDY DESIGN8-week-old and 50-week-old C57BL/6 J mice were used as young control (YC group) and aged controls (AC group), respectively. Then, aged mice were randomly divided into 5 groups (WSE100mg/kg, WSE200mg/kg, WSE400mg/kg, and schizandrin as a positive control) and fed each experimental diet for 10 weeks.METHODWe investigated the effects of WSE on muscle quality and protein homeostasis pathways based on improvements in mitochondrial function and chronic inflammation. We then used TNFα-treated C2C12 to investigate the effects of isoorientin (ISO) and isoschaftoside (ISS), the active substances of WSE, on the myogenic pathway.RESULTSWe administered WSE to aging mice and observed an increase in muscle mass, thickness, protein content, and strength in mice treated with WSE at a dose of 200 mg/kg or 400 mg/kg. Furthermore, the administration of WSE led to a reduction in inflammatory factors (TNFα, IL-1, and IL-6) and an increase in mitochondrial biogenesis (p-AMPK/SIRT3/PGC1α) in muscle. This effect was also observed in TNFα-induced muscle atrophy in C2C12 cells, and we additionally identified the upregulation of myogenic regulatory factors, including Myf5, Myf6, MyoD, and myogenin, by WSE, ISO, and ISS.CONCLUSIONThese findings suggest that WSE could function as a dietary anti-inflammatory factor and mitochondrial activator, potentially exerting modulatory effects on the metabolism and mechanical properties of skeletal muscles in the aging population. Furthermore, Our results demonstrate the potential value of ISO and ISS as functional food ingredients for preventing muscle atrophy.

100 项与睡茄提取物相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌萎缩侧索硬化	临床2期	加拿大	Sunnybrook Health Sciences Centre	2021-10-19
广泛性焦虑障碍	临床2期	印度	Natreon, Inc.	2011-03-01
精神分裂症	临床1期	美国	University of California, Los Angeles	2018-12-01
阿尔茨海默症	临床前	中国	华中科技大学	2022-12-20
阿尔茨海默症	临床前	美国	WellSpring School of Allied Health	2022-12-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03437668 (CTgov)	临床2/3期	精神分裂症	47	WSE (Withania Somnifera Extract (WSE))	醖選鏇鑰醖願網窪顧鏇(製淵製糧鹽餘築鏇鹹築) = 壓襯衊淵壓繭廠鹽鹽壓遞鑰網淵鏇願蓋網壓鬱 (鹽齋鏇壓遞夢選構築獵, 鑰糧獵糧襯積獵鹽衊網 ~ 夢選膚製製醖網繭範蓋) 更多	-	2024-10-08
				Placebo Oral Tablet (Placebo Tablets)	醖選鏇鑰醖願網窪顧鏇(製淵製糧鹽餘築鏇鹹築) = 膚構壓齋淵觸鬱餘遞壓遞鑰網淵鏇願蓋網壓鬱 (鹽齋鏇壓遞夢選構築獵, 積壓築艱製簾築憲淵淵 ~ 製壓鹹築選齋艱選構選) 更多